BioCryst Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioCryst Pharmaceuticals, Inc. (BCRX) on January 9, 2026. The report discloses a material event regarding the pricing of the Company's product, ORLADEYO® (berotralstat), effective as of the filing date.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the Wholesale Acquisition Cost (WAC) for ORLADEYO®:
- Previous WAC: $44,484.33 per 28-day pack (150mg or 110mg capsules).
- New WAC: $48,487.92 per 28-day pack (150mg or 110mg capsules).
- Effective Date: January 9, 2026.
Material Changes
The primary material change is the implementation of a price increase for ORLADEYO® in the United States. The WAC has increased by approximately $4,003.59 per 28-day pack, representing a price adjustment of roughly 9.0%.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies beyond the price adjustment itself. The document explicitly states that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the impact of the 9.0% price increase on future revenue projections and gross margins.
- Assess potential market reactions regarding patient access and insurance coverage for ORLADEYO® following the price hike.
- Review upcoming quarterly earnings reports for actual revenue realization relative to the new WAC.
- Confirm if this price adjustment aligns with the Company's previously stated commercial strategy.